CymaBay Therapeutics, Inc. logo

CymaBay Therapeutics, Inc.

NASDAQ:CBAY

Overview | Financials
Company Name CymaBay Therapeutics, Inc.
Symbol CBAY
Currency USD
Price 32.48
Market Cap 3,728,216,800
Dividend Yield 0%
52-week-range 7.261 - 32.5
Industry Biotechnology
Sector Healthcare
CEO Mr. Sujal A. Shah
Website https://www.cymabay.com

An error occurred while fetching data.

About CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis

Related Stocks

Mainz Biomed B.V. logo

Mainz Biomed B.V.

MYNZ

4.365 USD

Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc.

ALDX

6.91 USD

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

MIST

2.17 USD

Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc.

CODX

0.484 USD

Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc.

RYTM

50.97 USD

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.269 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Omeros Corporation logo

Omeros Corporation

OMER

8.42 USD

Financials

Numbers are in millions USD

Numbers are in millions USD